Acticor Biotech Announces the Recruitment of the First Patient in its Phase 2 GARDEN Study in COVID-19-related ARDS


– Approval of phase 2 GARDEN study in France and Brazil

– GARDEN will enroll 60 patients hospitalized for COVID19

– First Patient included at University Hospital of Strasbourg

Acticor Biotech is a clinical stage biotechnology spin-off of INSERM (built upon the expertise and the results of research conducted by the founders: Dr. Martine Jandrot-Perrus from U1148 Team 6 and Pr. Philippe Billiald at Paris-Sud University) is involved in the acute phase of thrombotic diseases, including acute ischemic stroke. Acticor today announces the recruitment of the first patient of its phase 2 GARDEN study to treat COVID-19-related acute respiratory distress syndrome (ARDS) with glenzocimab.

GARDEN ( NCT04659109) is a phase 2 study, randomized, double blind, multicenter, placebo controlled, parallel group, exploratory efficacy and safety study of glenzocimab in sars-cov-2-related acute respiratory distress syndrome. GARDEN will enroll 60 patients in France and in Brazil.

The first patient of the GARDEN study has been enrolled in University Hospitals of Strasbourg.

The primary objective of the study is to evaluate the effect of glenzocimab in preventing clinical progression of disease, when added to standard-of-care in COVID-19 patients presenting with acute respiratory distress syndrome. Glenzocimab might be an additional treatment option for COVID19 infected patients who present with ARDS. This treatment might also prevent downstream complications due to pro-thrombotic conditions.

Read the press release